Effects of the tirofiban on the application timing for coronary intervention
- VernacularTitle:替罗非班的应用时机对择期冠脉介入治疗的影响
- Author:
Xiao-Feng LIN
1
;
Kuan WANG
Author Information
1. 台州市第一人民医院 心内科
- Keywords:
tirofiban;
coronary heart disease;
percutaneous coronary in-tervention;
thrombolysis in myocardial infarction
- From:
The Chinese Journal of Clinical Pharmacology
2014;(5):394-396
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of early stage u-sing of tirofiban in the treatment of coronary atherosclerotic herat disease ( CAHD) by percutaneous coronary intervention ( PCI).Methods Two hundred and six cases with CAHD were included in this study and divid-ed into 3 groups.The perioperation group with 60 cases [ tirofiban using 24-hour before PCI, 0.4 μg· (kg· min) -1],ivggt,30 min, followed by 0.1μg· (kg· min) -1, the immediate group with 56 cases( tirofiban using in the procedure of PCI ) and the control group with 90 case(with-out tirofiban ).The platelet aggregation , thrombolysis in myocardial in-farction ( TIMI ) improvement and major cardiovascular events were com-pared among the three groups.Results The platelet aggregation was sig-nificant decreased in the three groups compared with prior PCI ( both P<0.05 ) , with the immediate group and perioperation group much lower than control group ( P <0.05 ) .The grade 3 TIMI was significant in-creased after PCI ( both P<0.05 ) with immediate group and periopera-tion group much higher than control group ( P<0.05 ) .The complication incidence in the control group was higher than that in immediate and perioperation groups ( P<0.05 ).Conclusion Tirofiban is safe in the treatment of CAHD by PCI which can significantly inhibit platelet aggre-gation and reduce the risk of acute thrombosis.
